Dr. Ansuman Satpathy, M.D., Ph.D., is a physician-scientist and Associate Professor of Pathology and Immunology at Stanford University. He is the director of the Stanford Center for Immunotherapy Design, co-director of the Parker Institute for Cancer Immunotherapy, and co-director of the Immunotherapy Program in the Stanford Cancer Institute. Ansu's research combines expertise in immunology, high-throughput genomics, and computation to discover principles of the immune system in health and disease and to translate these discoveries into novel clinical therapeutics.
The consistent focus of Dr. Anna Gloyn's research has been using naturally occurring mutations in humans as tools to identity critical regulatory pathways and insights into normal physiology. Her early post-doctoral research led to the identification a new genetic aetiology for permanent and transient neonatal diabetes due to KCNJ11 mutations and resulted in one of the first examples of precision medicine, where the determination of the molecular genetic aetiology lead to improved treatment options for patients. Whilst she was in Oxford, Dr.
Dr. Ann Mullally is a physician-scientist and Division Chief of Hematology. Dr. Mullally received her MD from University College Dublin, completed residency at Johns Hopkins and fellowship in hematology/oncology in the Brigham/Mass General/Dana-Farber program. Prior to moving to Stanford in 2024, Dr. Mullally was a Principal Investigator at Brigham and Women’s Hospital and a clinical faculty member at Dana-Farber Cancer Institute for approximately 10 years. Dr. Mullally is actively involved in all aspects of patient-oriented research.
